Learn About Alpers-Huttenlocher Syndrome

What is the definition of Alpers-Huttenlocher Syndrome?

Alpers-Huttenlocher syndrome is one of the most severe of a group of conditions called the POLG-related disorders. The conditions in this group feature a range of similar signs and symptoms involving muscle-, nerve-, and brain-related functions. Alpers-Huttenlocher syndrome typically becomes apparent in children between ages 2 and 4. People with this condition usually have three characteristic features: recurrent seizures that do not improve with treatment (intractable epilepsy), loss of mental and movement abilities (psychomotor regression), and liver disease.

Save information for later
Sign Up
What are the causes of Alpers-Huttenlocher Syndrome?

Alpers-Huttenlocher syndrome is caused by mutations in the POLG gene. This gene provides instructions for making one part, the alpha subunit, of a protein called polymerase gamma (pol γ). Pol γ functions in mitochondria, which are structures within cells that use oxygen to convert the energy from food into a form cells can use. Mitochondria each contain a small amount of DNA, known as mitochondrial DNA (mtDNA), which is essential for the normal function of these structures. Pol γ "reads" sequences of mtDNA and uses them as templates to produce new copies of mtDNA in a process called DNA replication.

How prevalent is Alpers-Huttenlocher Syndrome?

The prevalence of Alpers-Huttenlocher syndrome is approximately 1 in 100,000 individuals.

Is Alpers-Huttenlocher Syndrome an inherited disorder?

This condition is inherited in an autosomal recessive pattern, which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Who are the top Alpers-Huttenlocher Syndrome Local Doctors?
Elite
Highly rated in
9
conditions

Neurological Institute, Graduate School Of Medical Sciences, Kyushu University

Fukuoka, JP 

Katsuhisa Masaki is in Fukuoka, Japan. Masaki is rated as an Elite expert by MediFind in the treatment of Alpers-Huttenlocher Syndrome. They are also highly rated in 9 other conditions, according to our data. Their top areas of expertise are Tumefactive Multiple Sclerosis, Alpers-Huttenlocher Syndrome, Pelizaeus-Merzbacher Disease, and Multiple Sclerosis.

Elite
Highly rated in
8
conditions

University Of Sydney

Brain And Mind Centre 
Sydney, NSW, AU 

Todd Hardy is in Sydney, Australia. Hardy is rated as an Elite expert by MediFind in the treatment of Alpers-Huttenlocher Syndrome. He is also highly rated in 8 other conditions, according to our data. His top areas of expertise are Tumefactive Multiple Sclerosis, Alpers-Huttenlocher Syndrome, Susac Syndrome, and Pelizaeus-Merzbacher Disease.

 
 
 
 
Learn about our expert tiers
Learn more
Distinguished
Highly rated in
32
conditions

Neurological Institute, Graduate School Of Medical Sciences, Kyushu University

Brain And Nerve Center, Fukuoka Central Hospital 
Fukuoka, JP 

Jun-ichi Kira is in Fukuoka, Japan. Kira is rated as a Distinguished expert by MediFind in the treatment of Alpers-Huttenlocher Syndrome. He is also highly rated in 32 other conditions, according to our data. His top areas of expertise are Multiple Sclerosis, Tumefactive Multiple Sclerosis, Transverse Myelitis, and Optic Neuritis.

What are the latest Alpers-Huttenlocher Syndrome Clinical Trials?
The Myelin Disorders Biorepository Project and Global Leukodystrophy Initiative Clinical Trials Network
Match to trials
Find the right clinical trials for you in under a minute
Get started
Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy: A Key to Improving Sleep and Gait Performance
Who are the sources who wrote this article ?

Published Date:updated Last, June

Published By: National Institutes of Health

What are the Latest Advances for Alpers-Huttenlocher Syndrome?
POLG gene mutation. Clinico-neuropathological study.
Early and late outcomes after cord blood transplantation for pediatric patients with inherited leukodystrophies.
Tired of the same old research?
Check Latest Advances